Crown Equity Holdings Inc. (CRWE)
CRWE last trade was at $0.0096, up $0.0036 or 60%, with 142,000 shares traded so far
Looking to deliver value for its stockholders in both the near and long term, CRWE is refocusing its strategic plan for future growth and services with its original online business-to-business (B2B) marketplace platform for manufacturers and small to large businesses on a global basis to sell and acquire various types of merchandise, targeting the multi-billion dollar B2B Industry with its iB2B Global project.
Strategic plans are also being developed for CRWE ’s online video-sharing project to improve the potential future growth for the company, targeting this multi-billion dollar market with its Division CRWETube ( www.crwetube.com )
Together with its digital network of websites, CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher. CRWE focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .
****
GTx, Inc. (Nasdaq:GTXI)
GTXI stock is trading for about 1.84, up $0.10 or 5.75%, with more than 758,500 shares traded so far
GTXI reported that a poster presentation, entitled Results from two Phase 3 randomized trials of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer receiving chemotherapy, will be given by Jeffrey Crawford, M.D., Chief, Division of Medical Oncology at Duke University School of Medicine, and principal investigator for the POWER1 (platinum plus taxane) and POWER2 (platinum plus non-taxane) trials, which were chemotherapy add-on placebo controlled studies.
According to GTXI , top line results from the POWER trials showed that enobosarm 3 mg once daily had a significant effect on Lean Body Mass (LBM) through Day 84 and 147 in both trials, compared to placebo (taxane:p=0.0003 and <0.0001, respectively; non-taxane: p=0.0227 and 0.0036, respectively, using a continuous variable analyses).
Post-hoc landmark survival analyses at Day 84 suggest improved survival in patients who maintained or increased LBM in both clinical trials, regardless of treatment. As required by the study protocols, the final survival analysis will be completed after 450 deaths have been observed among patients in the studies.
Enobosarm was very well tolerated in both clinical trials.
Cancer-induced muscle wasting begins early in the disease process, resulting in decreased physical function and other detrimental consequences, such as fatigue and weight loss, which can contribute to disability, reduced quality of life and shorter overall survival, compared with patients without muscle loss.
The American Cancer Society estimates about 228,190 new cases of lung cancer will be diagnosed in the United States in 2013, and approximately 85 to 90 percent of these are non-small cell lung cancer. Approximately 159,480 Americans are expected to die from lung cancer this year.
GTXI is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions
More about GTx, Inc. (Nasdaq:GTXI) at www.gtxinc.com
**
Stamps.com Inc. (Nasdaq:STMP)
STMP is trading for about $47.37, representing an increase of $5.03 or 11.88%, with over 111,500 shares traded so far
For the third quarter ended September 30, 2013, STMP posted several record non-GAAP results, including record operating income of $10.1 million, which is up 21% year-over-year; record operating margin of 32.3%; record net income of $10.1 million, up 22% year-over-year; record earnings per fully diluted share of $0.62, which was up 24% year-over-year; and STMP also achieved year-over-year growth of 11% in paid customers in its core PC Postage business; record paid customers in its enterprise business, and strong total postage printed by its customer base, which was up 25% year-over-year.
According to its Business Outlook, STMP expects 2013 total revenue to be in a range of $125 to $135 million.
STMP ‘s GAAP net income per share for 2013 is expected to be in a range of $1.93 to $2.13; this compares to previous guidance of $1.73 to $1.93. GAAP net income per share includes approximately $4.5 million of stock-based compensation expense.
Excluding the stock-based compensation expense, STMP ‘s 2013 non-GAAP net income per fully diluted share is expected to be in a range of $2.20 to $2.40; this compares to previous guidance of $2.00 to $2.20.
STMP is a leading provider of Internet-based postage services. Stamps.com’s service enables small businesses, enterprises, advanced shippers, and consumers to print U.S. Postal Service-approved postage with just a PC, printer and Internet connection, right from their home or office.
More about Stamps.com Inc. (Nasdaq:STMP) at www.stamps.com
****
Read full discalimer at www.mikezaman.com/disclaimer
